Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose cytarabine vs high-dose daunorubicin in induction therapy for acute myeloid leukemia
KCT0004988Phase 3Recruiting
- Sponsor
- Asan Medical Center
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cytarabine, daunorubicin in acute myeloid leukemia (AML), sponsored by Asan Medical Center. Started Mar 2018; status: recruiting.
02
Drugs
cytarabinedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on KCT0004988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004988.